Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares gained 2.62% to $6.47. The company presented at UBS Global Healthcare Conference being held in New York. Harvey J. Berger, M.D., chairman and chief executive officer, provided overview of company’s business on May 20, 2014, at 4:00 p.m. (ET). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), weekly performance is -1.67%. On last trading day company shares ended up $6.49. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), distance from 50-day simple moving average (SMA50) is -11.09%.
MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced that it will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 2:30 pm (ET) in New York, New York. Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. Wells Fargo 2014 Healthcare Conference on Tuesday, June 17, 2014 at 10:00 am (ET) at the InterContinental in Boston, Massachusetts. MannKind Corporation (NASDAQ:MNKD), advanced 2.96% in last trading session and ended the day on $8.00. MNKD, return on assets is -82.40%. MannKind Corporation (NASDAQ:MNKD), quarterly performance is 22.32%.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), shares moved up 0.23% in last trading session and was closed at $51.89, while trading in range of $50.98 – 52.27. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), year to date (YTD) performance is 31.33%.
Shares of Dyax Corp. (NASDAQ:DYAX), which is developing a drug to treat a rare swelling disease called hereditary angioedema spiked after a Durham, N.C. biotech developing a similar drug reported data showing effectiveness in a mid-stage trial. Dyax Corp. (NASDAQ:DYAX), ended the last trading day at $8.41. Company weekly volatility is calculated as 9.63% and price to cash ratio as 6.10. Dyax Corp. (NASDAQ:DYAX), showed a positive weekly performance of 32.86%.
Express Scripts Holding Company (NASDAQ:ESRX)‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Friday. They currently have a $74.00 price target on the stock. Zacks‘s price objective would suggest a potential upside of 5.50% from the stock’s previous close. Express Scripts Holding Company (NASDAQ:ESRX), net profit margin is 2.10% and weekly performance is 2.58%. On last trading day company shares ended up $70.65. Analysts mean target price for the company is $79.26. Express Scripts Holding Company (NASDAQ:ESRX), distance from 50-day simple moving average (SMA50) is -1.74%.
Leave a Reply